A phase III randomised trial of 5 fraction prostate SBRT versus 5 fraction prostate and pelvic nodal SBRT

Trial summary:

PACE-NODES aims to compare prostate and pelvic nodal SBRT (PPN-SBRT) with prostate alone SBRT (P-SBRT) to determine whether PPN-SBRT has superior biochemical/clinical-failure free rate (reduces the risk of biochemical or clinical failure by 50% or more) than P-SBRT, in patients with high risk localised prostate cancer.  536 patients will be recruited from 25-30 UK and international sites over 2.5 years.

RT QA summary:

All QA activity will be streamlined with previous trial QA, where applicable. Please contact the RTTQA Group directly using the contact details below to discuss.

QA ProcessQA ActivityRequired for TrialAdditional Details
Pre-AccrualFacility QuestionnaireStreamlined
Outlining Benchmark CaseStreamlined
Planning Benchmark CasePPN-SBRT case
Dummy Run
During AccrualIndividual Case Review1 for each trial arm
Data collectionAll patients
QA StreamliningPACE, PEARLS and PIVOTALboost trials

RTTQA contact:

Chief investigator: Professor Nicholas van As

Co-clinical leads: Dr Angela Pathmanathan and Professor Suneil Jain

Sponsor: The Institute of Cancer Research (

Funder: Prostate Cancer UK (PCUK)